BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15067375)

  • 21. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
    Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
    J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of different molecular weight hyaluronan products on the expression of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis.
    Hsieh YS; Yang SF; Lue KH; Chu SC; Lu KH
    J Orthop Res; 2008 Apr; 26(4):475-84. PubMed ID: 17975844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upregulation of urokinase-type plasminogen activator and inhibitor and gelatinase expression via 3 mitogen-activated protein kinases and PI3K pathways during the early development of osteoarthritis.
    Hsieh YS; Yang SF; Lue KH; Chu SC; Li TJ; Lu KH
    J Rheumatol; 2007 Apr; 34(4):785-93. PubMed ID: 17299841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased expression of toll-like receptors in aseptic loose periprosthetic tissues and septic synovial membranes around total hip implants.
    Tamaki Y; Takakubo Y; Goto K; Hirayama T; Sasaki K; Konttinen YT; Goodman SB; Takagi M
    J Rheumatol; 2009 Mar; 36(3):598-608. PubMed ID: 19208601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis.
    Pappot H; Pedersen AN; Brünner N; Christensen IJ
    Lung Cancer; 2006 Feb; 51(2):193-200. PubMed ID: 16325301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abnormal regulation of urokinase plasminogen activator by insulin-like growth factor 1 in human osteoarthritic subchondral osteoblasts.
    Hilal G; Martel-Pelletier J; Pelletier JP; Duval N; Lajeunesse D
    Arthritis Rheum; 1999 Oct; 42(10):2112-22. PubMed ID: 10524682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toll-like receptors in the interface membrane around loosening total hip replacement implants.
    Takagi M; Tamaki Y; Hasegawa H; Takakubo Y; Konttinen L; Tiainen VM; Lappalainen R; Konttinen YT; Salo J
    J Biomed Mater Res A; 2007 Jun; 81(4):1017-26. PubMed ID: 17415764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tenascin-C levels in pseudosynovial fluid of loose hip prostheses.
    Hasegawa M; Sudo A; Nagakura T; Hirata H; Kinoshita N; Yoshida T; Uchida A
    Scand J Rheumatol; 2005; 34(6):464-8. PubMed ID: 16393770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of intra-articular administration of sodium hyaluronate on plasminogen activator system in temporomandibular joints with osteoarthritis.
    Tang YL; Zhu GQ; Hu L; Zheng M; Zhang JY; Shi ZD; Liang XH
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Apr; 109(4):541-7. PubMed ID: 20185343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
    De Cremoux P; Grandin L; Diéras V; Savignoni A; Degeorges A; Salmon R; Bollet MA; Reyal F; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X; Magdelénat H; Mignot L; Fourquet A;
    Anticancer Res; 2009 May; 29(5):1475-82. PubMed ID: 19443353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
    Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
    Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
    Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gelatinolytic and collagenolytic activity in periprosthetic tissues from loose hip endoprostheses.
    Syggelos SA; Eleftheriou SC; Giannopoulou E; Panagiotopoulos E; Aletras AJ
    J Rheumatol; 2001 Jun; 28(6):1319-29. PubMed ID: 11409126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progestin inhibits and thrombin stimulates the plasminogen activator/inhibitor system in term decidual stromal cells: implications for parturition.
    Norwitz ER; Snegovskikh V; Schatz F; Foyouzi N; Rahman M; Buchwalder L; Lee HJ; Funai EF; Buhimschi CS; Buhimschi IA; Lockwood CJ
    Am J Obstet Gynecol; 2007 Apr; 196(4):382.e1-8. PubMed ID: 17403427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
    Harbeck N; Kates RE; Gauger K; Willems A; Kiechle M; Magdolen V; Schmitt M
    Thromb Haemost; 2004 Mar; 91(3):450-6. PubMed ID: 14983219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.
    Osmak M; Babić D; Abramić M; Milicić D; Vrhovec I; Skrk J
    Neoplasma; 2001; 48(6):462-7. PubMed ID: 11949838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. uPA and PAI-1 in rectal cancer--relationship to radiotherapy and clinical outcome.
    Angenete E; Langenskiöld M; Palmgren I; Falk P; Oresland T; Ivarsson ML
    J Surg Res; 2009 May; 153(1):46-53. PubMed ID: 18533186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
    Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
    Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
    Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
    J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.